LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume

Journal of Pharmaceutical and Biomedical Analysis

Volumn 85, Issue , 2013, Pages 145-154

  Xu, Yaodong ^a   Yang, Yuan ^b   Smith, Lisa ^a   Edom, Rick ^a   Weng, Naidong ^a   Mamidi, Rao ^a   Silva, Jose ^a   Evans, David C ^a   Lim, Heng Keang ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

4 Hydroxycholesterol and cholesterol; CYP3A4 5 endogenous biomarker; FRG KO C57Bl 6 chimeric mice; LC ESI MS MS; Stable isotope labeled internal standard; Surrogate matrix

Indexed keywords

4 BETA HYDROXYCHOLESTEROL; CHOLESTEROL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ESTER; HUMAN SERUM ALBUMIN; OXYSTEROL; PHOSPHATE BUFFERED SALINE; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL TISSUE; ARTICLE; ASSAY; CHROMATOGRAPHY; COLLISIONALLY ACTIVATED DISSOCIATION; DERIVATIZATION; ELECTROSPRAY; ELUTION; ENZYMATIC ASSAY; HUMAN; HUMAN TISSUE; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; OXIDATION; PARTICLE SIZE; PLASMA; PLASMA VOLUME; PRECURSOR; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

4Β-HYDROXYCHOLESTEROL AND CHOLESTEROL; CYP3A4/5 ENDOGENOUS BIOMARKER; FRG KO C57BL/6 CHIMERIC MICE; LC-ESI-MS/MS; STABLE ISOTOPE-LABELED INTERNAL STANDARD; SURROGATE MATRIX;

ANIMALS; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROXYCHOLESTEROLS; MICE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84882732471     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.07.016     Document Type: Article

References (36)

1. Zhou S.F., Chan E., Li X.T., Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Therapeutics and Clinical Risk Management 2005, 1:3-13.
2. Sinz M., Wallace G., Sahi J. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS Journal 2008, 10(2):391-400.
3. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994, 270:414-423.
4. Thummel K.E., Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 1998, 38:389-430.
5. Turpault S., Brian W., Van Horn R., Santoni A., Poitiers F., Donazzolo Y., Boulenc X. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. British Journal of Clinical Pharmacology 2009, 68:928-935.
6. Ged C., Rouillon J.M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., Maurel P. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. British Journal of Clinical Pharmacology 1989, 28:373-387.
7. Galteau M.M., Sharma F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. European Journal of Clinical Pharmacology 2003, 59:713-733.
8. Kovacs S.J., Martin D.E., Everitt D.E., Patterson S.D., Jorkasky D.K. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clinical Pharmacology and Therapeutics 1998, 63:617-622.
9. Diczfalusy U., Miura J., Roh H.K., Mirghani R.A., Savi J., Larsson H., Bodin K.G., Allqvist A., Jande M., Kim J.W., Aklillu E., Gustafsson L.L., Bertilsson L. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenetics and Genomics 2008, 18:201-208.
10. Diczfalusy U., Nylén H., Elander P., Bertilsson L. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. British Journal of Clinical Pharmacology 2011, 71:183-189.
11. Lutjohann D., Marinova M., Schneider B., Oldenburg J., von Bergmann K., Bieber T., Bjorkhem I., Diczfalusy U. 4Beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. International Journal of Clinical Pharmacology and Therapeutics 2009, 47:709-715.
12. Fleishaker J.C., Pearson P.G., Wienkers L.C., Pearson L.K., Peters G.R. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. Journal of Pharmacology and Experimental Therapeutics 1996, 277:991-998.
13. Tomalik-Scharte D., Lutjohann D., Doroshyenko O., Frank D., Jetter A., Fuhr U. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?. Clinical Pharmacology and Therapeutics 2009, 86:147-153.
14. Peng C.C., Templeton I., Thummel K.E., Davis C., Kunze K.I., Isoherranen N. Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clinical Pharmacology and Therapeutics 2011, 89:888-895.
15. Yang Z., Rodrigues A.D. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?. Journal of Clinical Pharmacology 2010, 50:1330-1338.
16. de Serres M., Bowers G., Boyle G., Beaumont C., Castellino S., Sigafoos J., Dave M., Roberts A., Shah V., Olsen K., Patel D., Wagner D., Yeager R., Serabjit-Singh C. Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 2011, 41:464-475.
17. -/- mice. Nature Biotechnology 2007, 8:903-910.
18. Strom S.C., Davila J., Grompe M. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods in Molecular Biology 2010, 640:491-509.
19. Bodin K., Bretillon L., Aden Y., Bertilsson L., Broomé U., Einarsson C., Diczfalusy U. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. Journal of Biological Chemistry 2001, 276:38685-38689.
20. Simone J.B. Studies on cholesterol ester formation and hydrolysis in liver disease: a selective review. Yale Journal of Biology and Medicine 1979, 52:117-126.
21. Breuer O. Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. Journal of Lipid Research 1995, 36:2275-2281.
22. Dzeletovic S., Breuer O., Lund E., Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Analytical Biochemistry 1995, 225:73-80.
23. van de Merbel N.C., Bronsema K.J., van Hout M.W.J., Nilsson R., Sillén H. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2011, 55:1089-1095.
24. Goodenough A.K., Onorato J.M., Ouyang Z., Chang S., Rodrigues A.D., Kasichayanula S., Huang S.P., Turley W., Burrell R., Bifano M., Jemal M., LaCreta F., Tymiak A., Wang-Iversen D. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chemical Research in Toxicology 2011, 24:1575-1585.
25. Yamashita K., Kobayashi S., Tsukamoto S., Numazawa M. Synthesis of pyridine-carboxylate derivatives of hydroxysteroids for liquid chromatography-electrospray ionization-mass spectrometry. Steroids 2007, 72:50-59.
26. Honda A., Yamashita K., Miyazaki H., Shirai M., Ikegami T., Xu G., Numazawa M., Hara T., Matsuzakai Y. Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. Journal of Lipid Research 2008, 49:2063-2073.
27. van de Merbel N.C. Quantitative determination of endogenous compounds in biological samples using chromatographic techniques. Trends in Analytical Chemistry 2008, 27(10):924-933.
28. Fast D.M., Kelley M., Viswanathan C.T., O'Shaughnessy J., Peter King S., Chaudhary A., Weiner R., DeStefano A.J., Tang D. Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of Crystal City recommendations. AAPS Journal 2009, 11:238-241.
29. Tang Z., Guengerich F.P. Dansylation of unactivated alcohols for improved mass spectral sensitivity and application to analysis of cytochrome P450 oxidation products in tissue extracts. Analytical Chemistry 2010, 82:7706-7712.
30. Shinkyo R., Guengerich F.P. Inhibition of human cytochrome P450 3A4 by cholesterol. Journal of Biological Chemistry 2011, 286:18426-18433.
31. Stokvis E., Rosing H., Beijnen J.H. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?. Rapid Communications in Mass Spectrometry 2005, 19:401-407.
32. 2EDTA human plasma by LC-MS/MS. Proceedings of the 59th ASMS conference on mass spectrometry and allied topics, Poster # 667 2011.
33. Iverson S.J., Lang S.L.C., Cooper M.H. Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids 2001, 36(11):1283-1287.
34. DeBarber A.E., Lütjohann D., Merkens L., Steiner R.D. Liquid chromatography-tandem mass spectrometry determination of plasma 24S-hydroxycholesterol with chromatographic separation of 25-hydroxycholesterol. Analytical Biochemistry 2008, 381:151-153.
35. Williams J., Wood J., Pandarinathan L., Karanian D.A., Bahr B.A., Vouros P., Makriyannis A. Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Analytical Chemistry 2007, 79:5582-5593.
36. Lam P.M.W., Marczylo T.H., Konje J.C. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry 2010, 398:2089-2097.